60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
Investigational Review Board (IRB) approval has been granted for the open-label study…
First Breakthrough Study Highlights Superiority of MatriDerm in Wound Healing
MatriDerm® by MedSkin Solutions Dr. Suwelack AG Proven to Enhance Cell Activity,…
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
January 24, 2025 16:05 ET | Source: Akero Therapeutics Inc. Investor webcast…
First Breakthrough Study Highlights Superiority of MatriDerm in Wound Healing
MatriDerm® by MedSkin Solutions Dr. Suwelack AG Proven to Enhance Cell Activity,…
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
January 24, 2025 16:05 ET | Source: Akero Therapeutics Inc. Investor webcast…
First Breakthrough Study Highlights Superiority of MatriDerm in Wound Healing
MatriDerm® by MedSkin Solutions Dr. Suwelack AG Proven to Enhance Cell Activity,…
Elevar Therapeutics Presents Results from Post-Hoc Analysis of CARES-310 Study Evaluating the Impact of Viral and Non-Viral Etiology on Survival in Hepatocellular Carcinoma
January 24, 2025 10:41 ET | Source: Elevar Therapeutics Post-hoc analysis on…
First Breakthrough Study Highlights Superiority of MatriDerm in Wound Healing
MatriDerm® by MedSkin Solutions Dr. Suwelack AG Proven to Enhance Cell Activity,…
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreichs Ataxia
January 23, 2025 16:05 ET | Source: Larimar Therapeutics Adolescents receive a…
First Breakthrough Study Highlights Superiority of MatriDerm in Wound Healing
MatriDerm® by MedSkin Solutions Dr. Suwelack AG Proven to Enhance Cell Activity,…